295 related articles for article (PubMed ID: 18199797)
21. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
He Q; Lin C; Ji S; Chen J
Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
[TBL] [Abstract][Full Text] [Related]
22. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.
Shillingford JM; Murcia NS; Larson CH; Low SH; Hedgepeth R; Brown N; Flask CA; Novick AC; Goldfarb DA; Kramer-Zucker A; Walz G; Piontek KB; Germino GG; Weimbs T
Proc Natl Acad Sci U S A; 2006 Apr; 103(14):5466-71. PubMed ID: 16567633
[TBL] [Abstract][Full Text] [Related]
23. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.
Wüthrich RP; Serra AL
Transplant Proc; 2009; 41(6 Suppl):S18-20. PubMed ID: 19651290
[TBL] [Abstract][Full Text] [Related]
24. Kidney volume changes in patients with autosomal dominant polycystic kidney disease after renal transplantation.
Yamamoto T; Watarai Y; Kobayashi T; Matsuda Y; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Katayama A; Tominaga Y; Uchida K
Transplantation; 2012 Apr; 93(8):794-8. PubMed ID: 22491657
[TBL] [Abstract][Full Text] [Related]
25. Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease.
Kanaan N; Goffin E; Pirson Y; Devuyst O; Hassoun Z
Am J Kidney Dis; 2010 May; 55(5):916-22. PubMed ID: 20189277
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis.
Xue C; Dai B; Mei C
Nephron Clin Pract; 2013; 124(1-2):10-6. PubMed ID: 24022660
[TBL] [Abstract][Full Text] [Related]
27. Concomitant use of rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han:SPRD rats: a study of the mechanism of action.
Liu C; Li H; Gao X; Yang M; Yuan L; Fu L; Wang X; Mei C
Am J Physiol Renal Physiol; 2018 May; 314(5):F844-F854. PubMed ID: 26911848
[TBL] [Abstract][Full Text] [Related]
28. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
Serra AL; Kistler AD; Poster D; Struker M; Wüthrich RP; Weishaupt D; Tschirch F
BMC Nephrol; 2007 Sep; 8():13. PubMed ID: 17868472
[TBL] [Abstract][Full Text] [Related]
29. Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease.
Temmerman F; Chen F; Libbrecht L; Vander Elst I; Windmolders P; Feng Y; Ni Y; De Smedt H; Nevens F; van Pelt J
World J Gastroenterol; 2017 Aug; 23(30):5499-5507. PubMed ID: 28852309
[TBL] [Abstract][Full Text] [Related]
30. mTOR inhibitors in polycystic kidney disease.
Watnick T; Germino GG
N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
[No Abstract] [Full Text] [Related]
31. Volume regression of native polycystic kidneys after renal transplantation.
Jung Y; Irazabal MV; Chebib FT; Harris PC; Dean PG; Prieto M; Cosio FG; El-Zoghby ZM; Torres VE
Nephrol Dial Transplant; 2016 Jan; 31(1):73-9. PubMed ID: 26044834
[TBL] [Abstract][Full Text] [Related]
32. Intravascular embolization therapy in patients with enlarged polycystic liver.
Hoshino J; Ubara Y; Suwabe T; Sumida K; Hayami N; Mise K; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takei R; Takaichi K
Am J Kidney Dis; 2014 Jun; 63(6):937-44. PubMed ID: 24602778
[TBL] [Abstract][Full Text] [Related]
33. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.
Ruggenenti P; Gentile G; Perico N; Perna A; Barcella L; Trillini M; Cortinovis M; Ferrer Siles CP; Reyes Loaeza JA; Aparicio MC; Fasolini G; Gaspari F; Martinetti D; Carrara F; Rubis N; Prandini S; Caroli A; Sharma K; Antiga L; Remuzzi A; Remuzzi G;
Clin J Am Soc Nephrol; 2016 May; 11(5):785-794. PubMed ID: 26912555
[TBL] [Abstract][Full Text] [Related]
34. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
[TBL] [Abstract][Full Text] [Related]
35. mTOR inhibitors and autosomal dominant polycystic kidney disease.
Braun WE
N Engl J Med; 2011 Jan; 364(3):287; author reply 287-8. PubMed ID: 21247326
[No Abstract] [Full Text] [Related]
36. Do mTOR inhibitors still have a future in ADPKD?
Perico N; Remuzzi G
Nat Rev Nephrol; 2010 Dec; 6(12):696-8. PubMed ID: 21109768
[No Abstract] [Full Text] [Related]
37. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
[TBL] [Abstract][Full Text] [Related]
38. mTOR inhibitors and autosomal dominant polycystic kidney disease.
Grantham JJ; Bennett WM; Perrone RD
N Engl J Med; 2011 Jan; 364(3):286-7; author reply 287-9. PubMed ID: 21247328
[No Abstract] [Full Text] [Related]
39. Folate-conjugated rapamycin slows progression of polycystic kidney disease.
Shillingford JM; Leamon CP; Vlahov IR; Weimbs T
J Am Soc Nephrol; 2012 Oct; 23(10):1674-81. PubMed ID: 22859856
[TBL] [Abstract][Full Text] [Related]
40. mTOR inhibitors and autosomal dominant polycystic kidney disease.
Levey AS; Stevens LA
N Engl J Med; 2011 Jan; 364(3):287; author reply 287-9. PubMed ID: 21247327
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
